Hidradenitis suppurativa: I

Bukvić Mokos, Zrinka; Marinović, Branka

doi:10.1016/j.clindermatol.2023.08.017

Cited by 2 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several publications of ongoing clinical trials discuss the use of spesolimab (anti-IL-36 receptor) and JAK inhibitors, but so far there are too few reports to express a definitive opinion. [41][42][43][44][45][46][47][48][49][50][51][52][53][54][55][56][57][58] Larger Phase 3 studies will be needed to truly understand the efficacy and safety of these drugs for HS.…”

Section: Discussionmentioning

confidence: 99%

Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab: A 52-Week Real-Life Study

Martora,

Marasca,

Cacciapuoti

et al. 2024

CCID

View full text Add to dashboard Cite

Background:The treatment of hidradenitis suppurativa (HS) has always been a real challenge for dermatologists; to date, adalimumab the only biologic drug approved for HS is adalimumab, an anti-tumor necrosis factor (TNF)-α drug, the approval of this drug dates to 2015, data provided by real life show an effectiveness rate of about 60% percent. Recently (31 October 2023) FDA approves secukinumab for moderate-severe HS. The treatment and management of HS is very challenging as available treatments are very limited and show very variable outcomes. Methods: We conducted a prospective monocentric study designed to evaluate the efficacy and safety of secukinumab treatment in HS patients in a real-life setting. Results: The initial cohort of patients recruited included 21 HS patients including 12 females and 9 males. About 57.1% of patients achieved the primary endpoint and recorded significant decrease in all the severity assessment scales (IHS4, DLQI and VAS pain scale) at week 16 and 52, when HiSCR reached 71.4%. Conclusion:The results of our study highlight that treatment with secukinumab in patients with severe HS who failed adalimumab may be a safe and effective therapeutic weapon.

show abstract